| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC0750 |
| Trial ID | ChiCTR1800017439 |
| Disease | B-Cell Lymphoma | B-Cell Acute Lymphoblastic Leukemia | B-Cell Chronic Lymphocytic Leukemia |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Phase | Early_Phase1 |
| Recruitment status | Recruiting |
| Title | A clinical study using CD19-specific chimeric antigen receptor engineered T cells for the treatment of refractory/relapse B cell lymphoma, acute B lymphoblastic leukemia and chronic B lymphoblastic leukemia |
| Year | 2018 |
| Country | China |
| Company sponsor | Ludaopei Medical Group |
| Cohort 1 | |||||
|
|||||